Why African rare disease is a market, not a mission

The framing arrives before the spreadsheet does. When you mention rare disease in an African context, people reach instinctively for the language of philanthropy. They picture donor programmes, NGOs, a foundation logo on a clinic wall. The assumption is that where incomes are low and disease burden is high, the only honest motive is a charitable one. I think that assumption is lazy, and increasingly it is wrong. The unmet need is real, but unmet need is not the same thing as an unservable market. What has changed over the last few years is that the machinery for actually reaching these patients has quietly started to exist.

Need is not a market until you can transact

A market requires three things that charity does not: a buyer who can pay, a route by which the product legally moves, and a price that clears. For African rare disease, all three were genuinely absent for a long time, and that absence, not some failure of compassion, is why the sector looked like a mission.

The buyer question is the one most people get wrong. They assume the patient pays out of pocket, conclude that almost nobody can afford an orphan therapy, and stop there. But the buyer is rarely the patient. It is a medical scheme, a sovereign health budget, a regional risk pool, an employer plan for the formally employed, or in some cases a manufacturer's own access programme structured to seed a market it intends to grow into. South Africa alone has a private insured population in the millions, with medical schemes that already reimburse high-cost biologics. Kenya, Nigeria, Egypt and others are building or expanding national insurance mechanisms. The payer base is thin relative to Europe, but it is not zero, and it compounds.

The route question has moved fastest. Named-patient and compassionate-use pathways, Section 21 in South Africa being the clearest example, let unregistered medicines reach identified patients before full registration. The African Medicines Agency, slowly, is meant to reduce the duplication of forty-odd separate regulatory dossiers into something closer to a continental process. WHO prequalification gives a credible quality signal that procurement bodies trust. AfCFTA, if it delivers even a fraction of its promise on the movement of goods, changes the unit economics of distributing a low-volume, high-value product across borders. None of this is finished. All of it is directional, and it points the same way.

The economics of small numbers

Rare disease is, by definition, low volume. The instinct is that low volume plus low income equals no business. But orphan economics invert the usual logic. Value per patient is high, the diagnosed population is identifiable rather than diffuse, and the competitive field is thin because few firms bother. In a fragmented continent of underserved patients, the first credible operator to solve diagnosis, importation and reimbursement for a given condition does not face a price war. It faces an empty room.

That is the part that makes it commercial rather than charitable. Charity competes for grant cycles. A business that can reliably identify patients, secure named-patient authorisation, manage a cold chain that does not break between port and patient, and present a payer with a defensible reimbursement case is building something with real barriers to entry. The barriers are the regulation, the logistics and the relationships, which is precisely why generalists avoid the space and why incumbents, once established, are hard to dislodge.

There is a sequencing point too. Diagnosis comes first, and diagnosis is itself a market. You cannot treat what you cannot find, and across much of the continent rare conditions go uncoded, misdiagnosed, or simply unrecorded. Building the diagnostic layer, the laboratory networks, the genetic testing capacity, the registries, creates the denominator on which every later therapeutic conversation depends. It also happens to be a more durable, less binary business than betting on a single therapy. Infrastructure tends to outlast the product cycle.

Reading the moral disguise honestly

I want to be precise about what I am and am not saying. I am not saying the suffering is a pretext, or that the moral weight is fake. It is entirely real, and it is part of why these pathways are being built at all. Regulators extend compassionate-use routes because the human case is unanswerable. That moral pressure is doing genuine work on the policy environment, and an operator who pretends otherwise misunderstands the terrain.

What I am saying is that the moral framing has obscured a commercial one, and the obscuring has kept serious capital and serious operators away. The opportunity is hiding behind the assumption that it must be done at a loss. The truth is more interesting. The access pathways now being assembled, the named-patient routes, the harmonising regulation, the expanding insurance pools, the diagnostic infrastructure, are the load-bearing structure of a market. They were built under a moral banner, but what they actually constitute is plumbing. And plumbing, once laid, carries whatever you put through it.

The companies that understand this early will look, for a while, like they are doing good works. Some of them are. But the ones that endure will be the ones that recognised they were also building a business, priced it accordingly, and stayed long enough for the rest of the field to notice the room was no longer empty.